138 related articles for article (PubMed ID: 35442011)
1. Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects.
Shao J; Xu Z; Xu Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):537-548. PubMed ID: 35442011
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Kowalski K; Sandborn WJ; Feagan B
Clin Ther; 2022 Oct; 44(10):1336-1355. PubMed ID: 36150926
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
Tran L; Yao Z; Xu Z; Vermeulen A
Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
Ghosh S; Gensler LS; Yang Z; Gasink C; Chakravarty SD; Farahi K; Ramachandran P; Ott E; Strober BE
Drug Saf; 2019 Jun; 42(6):751-768. PubMed ID: 30739254
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
[TBL] [Abstract][Full Text] [Related]
8. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
Sandborn WJ; Feagan BG; Danese S; O'Brien CD; Ott E; Marano C; Baker T; Zhou Y; Volger S; Tikhonov I; Gasink C; Sands BE; Ghosh S
Inflamm Bowel Dis; 2021 Jun; 27(7):994-1007. PubMed ID: 32964215
[TBL] [Abstract][Full Text] [Related]
9. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
[No Abstract] [Full Text] [Related]
10. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease.
Wang Y; Marier JF; Lavigne J; Kassir N; Martin P
J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.
Xu Y; Hu C; Chen Y; Miao X; Adedokun OJ; Xu Z; Sharma A; Zhou H
J Clin Pharmacol; 2020 Jul; 60(7):889-902. PubMed ID: 32026499
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies.
Zhu Y; Wang Q; Frederick B; Bouman-Thio E; Marini JC; Keen M; Petty KJ; Davis HM; Zhou H
Clin Drug Investig; 2013 Apr; 33(4):291-301. PubMed ID: 23512638
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
[TBL] [Abstract][Full Text] [Related]
15. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
Rosh JR; Turner D; Griffiths A; Cohen SA; Jacobstein D; Adedokun OJ; Padgett L; Terry NA; O'Brien C; Hyams JS
J Crohns Colitis; 2021 Nov; 15(11):1931-1942. PubMed ID: 34037715
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
[TBL] [Abstract][Full Text] [Related]
18. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis.
Zhu YW; Mendelsohn A; Pendley C; Davis HM; Zhou H
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):830-46. PubMed ID: 21084039
[TBL] [Abstract][Full Text] [Related]
20. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Ko Y; Paramsothy S; Yau Y; Leong RW
Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]